Abstract 887P
Background
Locally advanced laryngeal carcinoma is treated by concomitant chemotherapy and radiotherapy then surgery whenever possible. Most patients between 60-70 years refuse surgery, therefore, we designed a treatment in order to postpone or evade the surgical option in elderly patients with T3 and T4 disease.
Methods
In this prospective phase II trial, we included 120 patients diagnosed with locally advanced laryngeal carcinoma (84 patients with T3 disease versus 36 patients with T4 disease) aged between (60-74 years) 67 years in median. Study was started by weekly paclitaxel at a fixed dose of 150mg and carboplatin AUC4 taken on days 1,8 and 15 of a 21-day schedule, cycles were repeated for 6 times. Then patients were evaluated by CT scan and laryngoscopy. Complete responders, partial and non-responders are referred to concomitant radiotherapy (60 Gy) with weekly cisplatin at 50mg for 6 weeks. Patients were followed up for a median of 42 months (38-57 months). Study end point was objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) for 3 years. Secondary end point was toxicity profile.
Results
ORR was observed in 116 patients (96.6%) evaluated by clinical exam, CT scan and laryngoscopy. Complete clinical response was documented in 87 patients after completion of chemotherapy 72.5% (95% CI: 66.2-79.1) and 27.5% partial responders (95% CI: 23.4-31.7). At 3 years of follow-up, PFS was 95% (95% CI: 92.7-98.8) (p value 0.001) while the OS at 3 years was 95%. We have lost 4 patients who died after hospitalization for severe neutropenia and renal failure. Surgery was deleted as an option in this category of patients. The toxicity profile was composed of different grades of neutropenia/thrombocytopenia and anemia. Reversable acute renal failure was seen in 5 patients as well as alopecia. Peripheral neuropathy with different grades was documented in 92 patients.
Conclusions
Neoadjuvant chemotherapy followed by concomitant chemo-radiotherapy in the light of feasibility and acceptable toxicity profile can be a substitution for surgery in elderly patients with locally advanced laryngeal carcinoma taking into consideration the good tolerance and the modest toxicity profile.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received anyfunding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
761P - Anti-angiogenic therapy in first-line treatment of low-grade serous ovarian cancer: Exploratory meta-analysis of the prospective AGO-OVAR 11/12/16 studies
Presenter: Bastian Czogalla
Session: Poster session 02
762P - First results from phase II dose expansion cohort of transcon IL-2 β/γ in combination with standard of care chemotherapy for platinum resistant ovarian cancer (PROC) in the IL Believe trial
Presenter: Oladapo Yeku
Session: Poster session 02
763P - Re-VOLVE: Phase II trial in women with ovarian cancer progressing post-PARP-inhibitor with treatment adapted to real-time assessment of evolving genomic resistance
Presenter: Pamela Soberanis Pina
Session: Poster session 02
765P - HER2 expression in ovarian cancer: Its relationship with HRD status, and other biomarkers
Presenter: Dahye Lee
Session: Poster session 02
766P - A phase II trial of fuzuloparib in combination with apatinib vs. fuzuloparib alone for recurrent ovarian cancer (OC)
Presenter: Jianqing Zhu
Session: Poster session 02
767P - Ovarian cancer risk factors in relation to family history
Presenter: Guoqiao Zheng
Session: Poster session 02
768P - Reclassification and variant distribution in the GINECO GREAT study of ovarian cancer patients: Insights into HRD status
Presenter: Etienne Rouleau
Session: Poster session 02
770P - Neoadjuvant pembrolizumab in stage IV ovarian cancer: The phase II Neo-Pembro trial
Presenter: Lot Aronson
Session: Poster session 02
771P - Claudin-6 expression in primary and recurrent epithelial ovarian cancer: A potential therapeutic target for high-grade serous ovarian cancer
Presenter: Daisuke Shintani
Session: Poster session 02